Ipsen, Syntaxin Partner to Develop Botulinum Toxin Drugs
By Nuala Moran
Friday, October 21, 2011
LONDON Ipsen SA has followed up an equity investment in Syntaxin Ltd with a research collaboration that will net the UK botulinum toxin specialist $9 million over three years for discovery work, with additional fees for any compounds that go into development, and a potential further $90 million in commercial milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.